Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Revenue of Xilio Therapeutics, Inc. (XLO)
Revenue in 2023 (TTM): $
According to Xilio Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Xilio Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-1,900,000 | $-73,804,000 | $-76,404,000 | $-76,404,000 |
| 2022 | $ | $-1,847,000 | $-85,575,000 | $-88,222,000 | $-87,295,000 |
| 2021 | $ | $-1,499,000 | $-73,701,000 | $-75,800,000 | $-74,301,000 |
| 2020 | $ | $-1,065,000 | $-53,498,000 | $-55,219,000 | $-55,219,000 |
| 2019 | $ | $-240,000 | $-17,071,000 | $-17,311,000 | $-17,311,000 |